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Background:We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a
biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.
Methods: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed
relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010
and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule
array) were assessed at baseline and up to four-year follow-up.
Findings: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying
2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with exist-
ing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients
(9.1 pg/ml, IQR 6.213.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.420.1 pg/ml, n = 213; p = 0.036). sNfL levels corre-Keywords:
Neurofilament light chain
sNfL
Multiple sclerosis
Prediction, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, Mainz, 55131, Germany. Phone:
ipp@uni-mainz.de (F. Zipp).
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Biomarker
Research in context
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port an earlier diagnosis of relapsing-remit
the 2017 McDonald criteria compared to th
on magnetic resonance imaging (MRI) o
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clinical and MRI parameters that are comm
tomonitor disease progression and treatmen
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2 S. Bittner et al. / EBioMedicine 56 (2020) 102807lated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-
modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients
(11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.415.3 pg/ml, n = 88). Therapy escalation decisions
within this period were reflected by longitudinal changes in sNfL levels.
Interpretation: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis
and may, particularly when measured longitudinally, facilitate therapeutic decisions.
Funding: Supported the German Federal Ministry for Education and Research, the German Research Council,
and Hertie-Stiftung.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Neuroaxonal damage is the major underlying pathologic substrate
of disability accumulation over time in patients with relapsing-remit-
ting multiple sclerosis (RRMS). Patients with existing signs ofNfL) levels have been
e inmultiple sclerosis
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d to find publications
eral publications sup-
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e 2010 criteria based
r clinical experience.
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only used in practice
t response. However,
igate the value of the
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t decision and only a
t the value of sNfL in
d syndrome (CIS) or
cDonald criteria and
iomarker capable of
e showed in a pro-
d McDonald criteria
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l the relation of sNfL
decisions within the
vations are of addi-
a young and initially
, this prognostically
d in robust publica-
14 patients with CIS
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y when it was mea-
peutic decisions and
n of patients. Longi-
absolute cut-off val-
making.neuroaxonal loss are at a high risk of developing secondary progres-
sive and disabling disease courses [1]. Various studies suggest that
tissue loss quantified by optical coherence tomography (OCT) [2,3] or
MRI assessment [4] could be used to predict subsequent disability.
However, both methods require either standardised longitudinal
measurements or entail technical challenges and have therefore not
yet been implemented in routine management. Serum neurofilament
light chain (sNfL) has recently been proposed as a possible candidate
for a reliable, easy-to-use biomarker of neuroaxonal damage [5]. Neu-
rofilament proteins are part of the neuronal cytoskeleton and are ele-
vated in various neurological diseases associated with neuronal
damage including neurodegenerative diseases [6] and stroke [7], as
well as MS [8]. Neurofilament light chain proteins are released after
axonal injury into the cerebrospinal fluid (CSF) and to a lesser extent
into the peripheral blood, where they can be measured by highly sen-
sitive single molecule assays (SiMoA) [5]. sNfL has been shown to cor-
relate with brain and spinal cord atrophy, as well as clinical relapses,
T2 lesion load, and gadolinium-enhancing (Gd+) lesions in patients
with RRMS [811]. However, to take the next step towards transla-
tion of sNfL into routine clinical use, there is a need for the investiga-
tion of large-scale real-world cohorts and longitudinal intra-
individual samples.
Recent findings by us and others have indicated that sNfL might
serve as a biomarker from very early stages of MS, namely in patients
with clinically isolated syndrome [8] (CIS), pediatric MS patients [12],
or even in presymptomatic stages of the disease [13]. This raises the
possibility that sNfL could be included in diagnostic algorithms. The
diagnosis of MS is based on McDonald criteria, which were first pre-
sented in 2001 and which underwent regular revisions in 2005, 2010
and 2017 as our understanding of this autoimmune CNS disease
improved. The basic pillars of the McDonald criteria are identification
of CNS lesions, using surrogate markers, and their dissemination in
time (DIT) and space (DIS).
The criteria enable the diagnosis of RRMS in patients already at
the first clinical presentation and to differentiate it from CIS, in which
the chronicity of established MS is not yet proven, as is reflected by a
lack of either DIT or DIS [14]. The definition of DIT has changed
markedly in the current 2017 McDonald revision by additionally
including a) symptomatic Gd+ lesions [15] and b) the presence of oli-
goclonal bands (OCB) in the CSF as a substitute for clinical or imaging
evidence of DIT. The intention was to define chronicity earlier in the
disease course allowing an earlier initiation of disease-modifying
therapy (DMT), which should improve long-term prognosis. Retro-
spective analysis of the 2017 McDonald criteria in different cohorts
[1618] has demonstrated that the current revision allows an earlier
diagnosis of RRMS compared to the 2010 criteria, in particular
through the use of OCB to fulfil the DIT criterion. Additional markers
are warranted to select patients at high risk of developing future dis-
ability (beyond making the diagnosis of MS per se) in order to initiate
early and effective treatment of RRMS patients.
We here address, in a multicentre approach in 814 patients from
the German National MS cohort with newly diagnosed CIS/RRMS, the
potential clinical implications of assessing sNfL in a real world setting
for diagnosis, prognosis, and therapeutic decisions.
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2.1. Mainz cohort
To assess the impact of 2010 versus 2017 McDonald criteria on
patients with newly diagnosed CIS and different levels of neuroaxo-
nal damage, we first performed a retrospective cross-sectional single
centre pilot study. Blood specimens of MS patients were collected
and processed at the University Medical Center Mainz as described
below. Datasets were available for 61 patients who had sNfL meas-
urements, MRI measurements, and CSF analysis at baseline. These
patients were initially classified according to 2010 McDonald criteria,
and patients with an initial diagnosis of CIS were reclassified accord-
ing to 2017 McDonald criteria.
2.2. German National MS cohort
The German National MS (NationMS) cohort is a multicentre pro-
spective longitudinal observational study comprising (a) detailed
assessment of patients with first diagnosis of MS or CIS according to
2005 McDonald criteria and (b) yearly assessment with a standar-
dised protocol across 22 centres in Germany. All centres belong to
the German Competence Network Multiple Sclerosis (KKNMS). The
study was approved by the ethics committee of Ruhr-University
Bochum (Registration no. 3714-10), and subsequently, by all local
ethics committees of the participating centres. All patients provided
written informed consent. Inclusion and exclusion criteria as well as
assessment plans have been described previously [19]. All patients
(n = 1,124) were included at least 30 days after relapse, but prior to
DMT initiation. Thereafter, DMT was initiated in a “real world” setting
by each centre. Complete datasets were available for 814 patients
who had sNfL measurements and MRI at baseline and were followed
up at least two years. For an additional 598 patients, clinical parame-
ters were available after four years of follow-up. To exclude a selec-
tion bias, we analyzed baseline and clinical characteristics of both
cohorts (814 vs 1124 patients in the whole NationMS cohort) for age,Table 1
Clinical and demographic data of CIS/early RRMS
included in this study at baseline.
Variable CIS
n 369
Median (
sNfL (pg/mL) 10.1 (6.9
Age (years) 33 (264
EDSS 1.5 (12
Mean §
Disease duration (months) 2 (12)
n (%)
Sex male 113 (30.6
female 256 (69.4
OCB neg. 23 (6.2%
pos. 188 (50.9
unknown 158 (42.8
T2-lesion count 18 110 (30.1
> 8 256 (69.9
unknown 3 (0.8%)
GD-enhancement no 269 (75.6
yes 85 (23.9%
unknown 2 (0.6%)
Ring-enhancement no 321 (93.9
yes 21 (6.1%
unknown 27 (7.3%
Treatment no treatment 369 (100
IQR: interquartile range; CIS: clinically isolated sy
sclerosis; sNfL: serum neurofilament light chain; E
oligoclonal bands; SD: standard deviation.
aMannWhitney-U tests were conducted to compa
bDistributions were compared using chi-square testsex, disease duration, first clinical manifestation, and extended dis-
ability status scale (EDSS) and found no major differences for all
parameters arguing against a selection bias. In our cohort the median
age at inclusion was 33 years (IQR 26-41 years) compared to
32.4 years (26.641.0 years) in the total cohort. We reported a base-
line EDSS median of 1¢5 (IQR 1.0-2.0) which is in line with the median
reported in the entire cohort ([19] and Table 1). For our study,
patients were classified according to 2010 McDonald criteria, and
patients with an initial diagnosis of CIS were reclassified according to
2017 McDonald criteria.
2.3. sNfL measurements
To ensure a high degree of standardisation, blood withdrawal was
performed at the same day of MRI investigation but before the appli-
cation of contrast medium using a standard protocol in all centres.
Blood was collected in 10 ml Serum-Vacutainer-tubes (Becton Dick-
inson, USA); samples were spun at 1300 g at room temperature for
15 min within 2 h after sampling. Directly after centrifugation, the
serum was evenly transferred (300600 ml/tube) in 1¢1 ml polypro-
pylene tubes and locally stored at 80 °C. Serum samples from all
centres were then sent on dry ice to the KKNMS biobank and cen-
trally stored at 80 °C.
In a previous study, several days of processing did not signifi-
cantly affect NfL levels in plasma, indicating stability of the protein
and a robust assay procedure [20]. For this project, serum samples of
our included patients were sent on dry ice from the central biobank
in Munich to Mainz. Here, measurements from the multicentre
cohort were performed in one single centre at one machine with a
standardised protocol and a single batch. sNfL was measured in sev-
eral rounds by SiMoA HD-1 (Quanterix, USA) using the NF-Light
Advantage Kits (Quanterix) from the same batch according to manu-
facturer’s instructions. Resorufin-b-D-galactopyranoside (RGP) was
incubated at 33 °C for 60 min prior to running the assay.
Samples were measured in duplicates. The coefficient of variation
(CV, as a percentage) of each sample was obtained by dividing thepatients according to 2010 McDonald criteria
RRMS p-value
445
IQR)
17.1) 12.5 (8.022.8) <0.0005a
1) 31 (2640) 0.272a
) 1.5 (12) 0.010a
SD: 1.3 § 1.0 1.5 § 1.0
2 (13) 0.141a
p-value
%) 146 (32.8%) 0.505b
%) 299 (67.2%)
) 23 (8.9%) 0.593b
%) 222 (86.0%)
%) 13 (5.0%)
%) 132 (29.8%) 0.936b
%) 311 (70.2%)
2 (0.4%)
%) 218 (50.3%) <0.0005b
) 213 (49.2%)
2 (0.5%)
%) 364 (89.0%) 0.019b
) 45 (11.0%)
) 36 (8.1%)
%) 445 (100%)
ndrome; RRMS: relapsing-remitting multiple
DSS: Expanded Disability Status Scale; OCB:
re group differences.
s of homogeneity.
4 S. Bittner et al. / EBioMedicine 56 (2020) 102807standard deviation of both replicates by the mean of both replicates
multiplied by 100. Since the range of sNfL concentrations in serum is
smaller than in CSF, some samples with a sample CV above 20% (or
missing replicate result) were measured twice, as in previous publi-
cations [8,9]. Finally, the mean intra-assay CV of 6.2% was obtained
by averaging all individual sample CVs. The two same low and high
controls, consisting of recombinant human NfL antigen, were run in
duplicates with each sample run to monitor plate-to-plate variation.
The mean concentration over all runs was 4.4 pg/ml for the low con-
trol and 141.5 pg/ml for the high control. We obtained inter-assay
CVs of 6.0% and 13.2% for the low and high control, respectively. sNfL
measurements were performed in a blinded fashion without infor-
mation about clinical data.
2.4. Multiple Sclerosis Functional Composite (MSFC)
The MSFC is a score composed of three objective quantitative neuro-
logical tests for assessing arm, leg, and cognitive function and was devel-
oped to improve the measurement of clinical outcome in extension to
the EDSS [21]. Subtests of the MSFC in the NationMS cohort have
recently been published to investigate changes in cognitive impairment
from baseline up to 12months [22]. We here used our baseline cohort as
a reference population for the z-standardisation instead of normative
control cohorts in the previous publication, which leads to different z-
scores without affecting the ratio of the amount of change to the stan-
dard deviation of the change. A detailed description of the administration
and calculation of the MSFC were already published [23]. Z-scores were
obtained by standardising all subtest scores to the baseline results of all
patients included in this study. Finally, the MSFC score was calculated
using the following formula: MSFC score = (Z-score TW + Z-score
9-HPT + Z-score PASAT)/3. (TW = Timed 25-Foot Walk; 9-HPT = Nine-Hole
Peg Test; PASAT = Paced Auditory Serial Addition Test).
2.5. Statistics
Statistical analyses were performed with SPSS version 23 (IBM
Corp., USA), MATLAB R2018a (MathWorks, USA) and RStudio version
1.1.456 (RStudio Inc., USA). The normal distribution of data was
tested using the KolmogorovSmirnov and ShapiroWilk tests. We
used a MannWhitney test or KruskalWallis-Test with adjusted p
values by Bonferroni correction, as appropriate. Effect size after
applying a MannWhitney-U test was estimated using the formula
(r2 ¼ h2 ¼ Zffiffi
n
p ) where Z is the standardised value for the U-value, r the
correlation coefficient, and r2 or h2 indicate the percentage of vari-
ance in the dependent variable that can be explained by the indepen-
dent variable when multiplied by 100%. Non-parametric correlation
was determined by Spearman's rank correlation coefficient and par-
tial non-parametric correlation when considering age as a covariate.
Age as cofounding factor needs to be taken into account in older
patients as sNfL seems to considerably increase in particular above
the age of 60 years with rather stable values in younger patients [24].
In agreement, in our cohort of mainly young patients (median age
32 years, percentage of patients > 60 years old: 0.7%), we found no
significant correlation between age and sNfL values (r = 0.044,
p = 0.21, Supplementary Fig. 1A+B) and hence no age correction was
necessary. However, all analyses were additionally performed with
age as a covariate using one-way or two-way mixed ANCOVA where
appropriate and can be found in Supplementary Table 1. Within-sub-
ject factors over time were analyzed by mixed linear models or two-
way mixed ANOVA after log-transformation of sNfL values. This was
followed by one-way ANOVA with Tukey post-hoc test for multiple
comparison to calculate simple main effects. Delta sNfL values (two-
year follow-up minus baseline) were reflected and set to a minimum
of 1 followed by non-negative transformation of the resulting values.
A Chi-square test of homogeneity was applied to investigate differen-
ces in proportions. When performed, post hoc analysis involvedpairwise comparison using multiple z-test of two proportion with a
Bonferroni correction. Boxplots are shown with the median repre-
sented by a horizontal line. Boxes extend from the 25th to 75th per-
centile. The upper whiskers expand from the 75th percentile to the
highest value that is smaller than or equal to the interquartile range
(IQR) multiplied by 1.5 and added to the 75th percentile. The lower
whiskers extend from the 25th percentile to the smallest value that
is higher or equal to the IQR multiplied by 1.5 and subtracted from
the 25th percentile. For better visualisation, scatterplots were graphi-
cally modified using the syntax command dodge (Fig. 1A) or jitter (all
other figures) in SPSS. All statistical analyses were performed using
the original data without modifications. P values < 0.05 were consid-
ered statistically significant.
2.6. Bayesian analyses
To deal with imbalanced sample sizes for data with a non-Gauss-
ian distribution (Fig. 2C and D), we used the Bayesian posterior distri-
bution analyses as additional validation of significant group
differences already determined by MannWhitney-U tests. This anal-
ysis provides complete distribution of credible values for group
means and their differences [25]. Specifically, we tested for sNfL
markers based on the two groups with and without taking age as a
covariate for the capability of credible separation.
2.7. Composite score analyses
Composite scores were calculated in a two-step procedure. First,
we performed a cluster analysis by grouping all possible combina-
tions (always a pair) for the variables that had an area under the
curve (AUC) > 0.5. Second, from the significant (p < 0.05) clusters
corrected for multiple comparisons using Bonferroni corrections, we
estimated a composite score using the partial least squares method
(PLS) to assign the weights for each combination [26].
See also Supplementary Methods for more detailed methods.
3. Results
The overall aim of the study was to assess potential clinical impli-
cations of measuring sNfL for diagnostic accuracy, prognosis, and
therapeutic decisions in early MS patients. To evaluate the impact of
2010 versus 2017 McDonald criteria on patients with newly diag-
nosed CIS and different levels of neuroaxonal damage, we first per-
formed a pilot study. Patients diagnosed with CIS according to 2010
McDonald criteria (CIS[2010]) were reassessed and classified either
as CIS or RRMS based on the 2017 criteria (CIS[2017], RRMS[2017]).
Interestingly, in this single-center cohort, sNfL levels were higher in
RRMS (8.9 pg/ml, IQR 5.514.3 pg/ml, n = 30) than in CIS patients
according to the new criteria (4.7 pg/ml, IQR 3.68.5, p = 0¢001,
Fig. 1A). Based on this promising data, we designed a multicentre
approach (Fig. 1B) where 814 patients were included at baseline and
up to four-year follow-up (for baseline characteristics see Table 1). At
baseline and year two, patients with 9 cranial T2 lesions according
to Barkhof criteria [27] had significantly higher sNfL levels (baseline:
13.0 pg/ml, IQR 8.223.5 pg/ml, n = 567; two year follow-up: 8.4 pg/
ml, 6.112.2 pg/ml, n = 573) than those with 1-8 T2 lesions (baseline:
8.6 pg/ml, IQR 6.112.9 pg/ml, n = 242; p < 0.0005; two-year follow-
up: 7.0 pg/ml, 5.79.0 pg/ml, n = 161, p = 0.001, Fig. 1C). Comparable
findings were obtained for sNfL and Gd+ lesions as Gd+ lesions corre-
lated with high sNfL levels in all patients (Fig. 1D). Furthermore, we
found a weak correlation between sNfL and EDSS values (r = 0.13, p <
0.0005), between sNfL levels and ring enhancing lesions (Supplemen-
tary Fig. 2A+B), and an inverse correlation between sNfL levels and
MSFC score at baseline and two-year follow-up (r = -0.170, p <
0.0005, Fig. 1E). Patients who suffered from at least one relapse in the
following two years had significantly higher levels at baseline
Fig. 1. sNfL at time point of diagnosis correlates with baseline MRI parameters in a multicentre cohort and predicts clinical activity within the next two years. A) In a single-centre
pilot study, patients with CIS according to 2010 McDonald criteria (n = 61; CIS[2010]) were reclassified based on the 2017 version of the McDonald criteria. sNfL levels were signifi-
cantly higher in patients switching to RRMS (8.9 pg/ml, IQR 5.5-14.3 pg/ml, n = 30; RRMS[2017]) compared to patients remaining CIS (4.7 pg/ml, IQR 3.6-8.5 pg/ml, n = 31; CIS
[2017]; p = 0.001 determined by MannWhitney-U test). B) Study design of a multicentre approach to assess reclassification of CIS[2010] patients according to 2017 McDonald cri-
teria. C) 1543 MRIs from 809 patients were assessed for sNfL levels comparing MRIs with> 8 T2 lesions (baseline: n = 567; two-year follow-up: n = 573) and 1-8 T2 lesions (baseline:
n = 242; two-year follow-up: n = 161). sNfL was higher in patients with> 8 than 1-8 T2 lesions at baseline (13.0 pg/ml, IQR 8.2-23.5 pg/ml; 8.6 pg/ml, IQR 6.1-12.9 pg/ml, p< 0.0005)
and two-year follow-up (8.4 pg/ml, IQR 6.1-12.2 pg/ml; 7.0 pg/ml, IQR 5.7-9.0 pg/ml, p = 0.001). Both lesion groups showed a significant decrease of sNfL concentration after two
years. D) Patients with Gd+ lesions at the time of serum sampling (n = 298; two-year follow-up: n = 94) had significantly higher sNfL levels than patients without Gd+ lesions
(n = 487; two-year follow-up: n = 606). E) Baseline and two-year follow-up sNfL levels were negatively correlated with corresponding MSFC values (r = -0.170, p < 0.0005). F) sNfL
S. Bittner et al. / EBioMedicine 56 (2020) 102807 5
6 S. Bittner et al. / EBioMedicine 56 (2020) 102807compared to patients experiencing no further relapses (12.2 pg/ml,
IQR: 7.922.2 pg/ml, n = 337; no relapse: 10.6 pg/ml, IQR:
7.922.2 pg/ml, n = 477; p = 0.015, Fig. 1F). In agreement with this,
we found a correlation between baseline sNfL levels and the absolute
number of relapses in this two-year period (r = 0.092, p = 0.008,
Fig. 1G). In order to further evaluate the predictive value of baseline
sNfL values after diagnosis for future risk stratification, we developed
a risk score using support vector machine (SVM) algorithms (see Sup-
plementary Material and Methods). Using the two MRI parameters i)
presence or absence of Gd+ lesions and ii) 1-8 T2 lesions or more, a
composite risk score was assigned to each individual patient at base-
line. The predictive capacity of the risk score for the two outcome
parameters EDSS and MSFC in a two-year follow-up was calculated
by SVM analysis. Correlation coefficients drastically increased by
including the sNfL baseline values in the composite risk score (EDSS:
0.32 to 0.40, MSFC: 0.30 to 0.44, Fig. 1H), underlining that evaluation
of both MRI parameters and sNfL had an added-value compared to
only using one single approach.
Out of the 814 patients at disease onset, 45.3% (n = 369) had a
diagnosis of CIS[2010] and 54.7% (n = 445) had a diagnosis of RRMS
[2010] (Fig. 2A). sNfL levels were higher in RRMS[2010] (12.5 pg/ml,
IQR 8.022.8 pg/ml, n = 445) than in CIS[2010] (10.1 pg/ml, IQR 6.9-
17.1 pg/ml, n = 369, p < 0.0005, Fig. 2B) despite similar baseline char-
acteristics such as disease duration (Table 1). When applying the
2017 McDonald criteria to the same patients, both the presence of
OCB and the assessment of symptomatic Gd+ lesions could change
the classification of CIS[2010] to RRMS[2017]. We excluded 111
patients due to missing information regarding DIT. To prevent a
selection bias, subgroup analyses were performed showing no signifi-
cant differences (see Supplementary Table 2). Upon reclassification of
CIS[2010] patients with existing CSF analysis, according to 2017 crite-
ria, only 17.4% (45/258) remained CIS[2017] whilst 82.6% (213/258)
were reclassified as RRMS[2017]. Importantly, patients who were
reclassified from CIS[2010] to RRMS[2017] had elevated sNfL levels
(10.8 pg/ml, IQR 7.420.1 pg/ml, n = 213) compared to CIS[2010]
patients remaining CIS[2017] (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45,
p = 0.036, Fig. 2C). Taking into account the imbalanced sample sizes,
this analysis was additionally confirmed by Bayesian analysis, which
resulted in a discrimination accuracy of 93.0%. These findings demon-
strate that application of 2017 McDonald criteria to CIS patients
results in diagnosis of RRMS compared to a diagnosis of CIS when
applying the previous McDonald criteria in patients with increased
neuroaxonal damage. Additionally, we evaluated whether the pres-
ence or absence of OCB and Gd+ in RRMS[2010] patients separates
patients with high and low sNfL levels. Both OCB-positive RRMS
[2010] patients (13.1 pg/ml, IQR 8.024.3 pg/ml, n = 222) and RRMS
[2010] patients with Gd+ lesions (16.4 pg/ml, IQR 9.331.3 pg/ml,
n = 213) had significantly higher sNfL levels than OCB-negative
(10.1 pg/ml, IQR 6.715.8 pg/ml, n = 23, p = 0.035, accuracy of
discrimination = 96.4%) and Gd-negative (10.2 pg/ml, IQR
7.216.1 pg/ml, n = 218, p < 0.0005) patients (Fig. 2D+E).
To unravel whether inclusion of sNfL in the McDonald diagnostic
criteria algorithm would increase the discrimination accuracy
between patients with CIS and RRMS, receiver operating characteris-
tic (ROC) analysis was performed in order to reclassify CIS[2010] as
CIS[2017] or RRMS[2017]. Inclusions of the 90th percentile of sNfLlevels at baseline were significantly higher in patients suffering at least one relapse up to
(median: 10.6 pg/ml, IQR: 7.9-22.2 pg/ml, n = 477, p = 0.015). G) Baseline sNfL levels correla
baseline risk score consisting of either presence of Gd+ lesions and T2 lesions (1-8 lesions or
sNfL (EDSS cutoff point = 15.48; MSFC cutoff point = 17.21) was determined for risk stratificat
ters EDSS (YI = 1.54) and MSFC (YI = 0.3) and at FU2 was assessed by SVM algorithm. Correlat
of baseline sNfL levels in the risk score computation. 10-fold cross validation was performed
cations are depicted in the table. Group differences were analyzed by mixed linear model p
rank correlation coefficient after exclusion of normally distributed data by Kolmogorov-Sm
two year follow-up, Gd: gadolinium enhancing lesions, OCB: oligoclonal bands, RRMS: relaps
rofilament, MSFC: Multiple Sclerosis Functional Composite, YI: Youden's index, SVM: suppor(31.2 pg/ml) led to a significantly increased (p = 0.035) area under
the curve (AUC = 0.84, CI 0.79 0.89, p < 0.0005) compared to OCB
and/or Gd+ (AUC = 0.76, CI 0.700.83, p < 0.0005, Fig. 2F). We con-
firmed these linear classification data by predictive analysis using a
machine learning algorithm SVM which is a non-linear classifier.
Importantly, the prediction accuracy of OCB and/or Gd+ (sensitivity:
72%, specificity: 76%, accuracy: 79%) were again further increased by
including the 90th percentile of sNfL in addition to the above two
variables (sensitivity: 73%; specificity: 79%, accuracy: 84%; Fig. 2G, for
more data on 50th to 90th percentile see Supplementary Table 3).
These findings point towards a potential value of especially high sNfL
levels (>31 pg/ml) at time of first demyelinating event as indicators
of ongoing chronic CNS neuroinflammation and may be considered
for inclusion in a future refinement of the McDonald criteria.
The changes in the 2017McDonald criteria are intended to allow ear-
lier diagnosis of RRMS and thus to facilitate initiation of DMT as early as
possible in these patients [28]. Therefore, we assessed whether sNfL lev-
els can predict later initiation of DMT and whether treatment would
influence sNfL levels after two years of follow-up. The percentage of
patients under therapy at two-year follow-up was comparable between
CIS[2010] (76% (279/369)) and RRMS[2010] (81% (359/445)) patients
(Fig. 3A). Reclassification of CIS[2010] patients according to 2017 criteria
had no impact on whether DMT were administered or not (Fig. 3A). At
baseline, all patients were treatment naïve. Indeed, patients without
DMT initiation during the first two years showed lower sNfL levels at
baseline (9.5 pg/ml, IQR 6.414.1 pg/ml, n = 87) than patients with at
least one (transient) DMT during the observation period (11.8 pg/ml, IQR
7.520.9 pg/ml, n = 727, p = 0.002, Fig. 3B). We next grouped patients
into four classes based on the type of DMT they were receiving at two-
year follow-up (“no DMT”: n = 176; “basic”: interferons and glatiramera-
cetate, n = 392; “moderate”: teriflunomide and dimethylfumarate,
n = 134; and “high”: natalizumab, rituximab, fingolimod, ocrelizumab,
daclizumab, alemtuzumab, mitoxantrone, n = 107). Five patients were
excluded from DMT analysis due to unknown treatment. Of note, sNfL
baseline levels significantly correlated with the established treatment
group at two-year follow-up (r=0.223, p<0.0005, Fig. 3C). While all treat-
ment groups had comparable sNfL levels after two years (no DMT:
8.4 pg/ml, IQR 6.211.6 pg/ml; “basic”: 7.7 pg/ml, IQR 5.811.4 pg/ml;
“moderate”: 7.5 pg/ml, IQR 5.611.0 pg/ml; “high”: 8.2 pg/ml, IQR
6.411.6 pg/ml; all p > 0.05), patients on “high” therapies had signifi-
cantly elevated baseline levels (“high”: 21.0 pg/ml, IQR 12.045.3 pg/ml)
compared to other groups (no DMT: 10.0 pg/ml, 6.618.3 pg/ml, p <
0.0005; “basic”: 10.5 pg/ml, 7.117.1 pg/ml, p < 0.0005; “moderate”:
12.0 pg/ml, 7.422.0 pg/ml, p< 0.0005; Fig. 3D). This indicates that high
sNfL levels at disease manifestation correlate with real world therapy
decisions since sNfL levels were not known to treating physicians at the
time point of treatment initiation. After adjustment for the baseline sNfL
concentrations, comparing the delta sNfL values (two-year follow-up
minus baseline) of the different treatment groups between each other
further showed a massive sNfL decline in the “high” treatment group
(median 11.3 pg/ml, IQR 37.3 to 2.9 pg/ml) that was significantly
higher than in the “basic” group (2.2 pg/ml, 7.6 to 0.8 pg/ml,
p = 0.001) and no DMT group (0.8 pg/ml, 6.5 to 1.6 pg/ml, p = 0.001,
Fig. 3E). This might be due to resolving initial inflammation (regression
to the mean phenomenon), as all patients were included at least 30 days
after relapse, but prior to DMT initiation, and acute inflammatoryFU2 (median: 12.2 pg/ml, IQR: 7.9-22.2 pg/ml, n = 337) than patients without relapse
ted with the number of relapses between baseline and FU2 (r = 0.092, p = 0.008). H) A
more than 8) alone (EDSS cutoff point = 1.94; MSFC cutoff point = 1.68) or in addition to
ion at study initiation. The predictive power of the model for the two outcome parame-
ion coefficients were increased (EDSS: 0.32 to 0.40, MSFC: 0.30 to 0.44) by the inclusion
for the correlation and accuracy parameters. Detailed information on the model specifi-
rocedure or Mann-Whitney-U test. Correlation analysis was performed by Spearman's
irnov-Test and Shapiro-Wilk-Test. BL: baseline, CIS: clinically isolated syndrome FU2:
ing remitting multiple sclerosis, T2: lesions in T2 weighted MRI scans, sNfL: serum neu-
t vector machine. **p < 0.01, ***p < 0.001.
Fig. 2. Application of 2017 McDonald criteria selects patients with increased neuroaxonal damage. A) Flowchart of the study design. B) RRMS[2010] patients (n= 445) had signifi-
cantly higher sNfL levels than CIS[2010] patients (12.5 pg/ml, IQR 8.0-22.8 pg/ml, n = 445; 10.1 pg/ml, IQR 6.9-17.1 pg/ml, n = 369, p < 0.0005). C) Application of 2017 McDonald cri-
teria to CIS[2010] patients (n = 369) differentiated CIS[2017] (n = 45) from RRMS[2017] (n = 213) patients and resulted in significantly higher sNfL levels in patients reclassified to
RRMS[2017] (10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213) compared to patients remaining CIS[2017] (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45, p = 0.036 determined by MannWhitney-U
test and 93.0% accuracy of discrimination computed by Bayesian analysis with caution of the imbalanced sample size). D) sNfL levels were significantly higher in RRMS[2010]
patients with positive OCB (13.1 pg/ml, IQR 8.0-24.3 pg/ml, n = 222) compared to those without (10.1 pg/ml, IQR 6.7-15.8 pg/ml, n = 23, p = 0.035, discrimination accuracy = 96.4%).
E) Significantly higher sNfL levels were found in RRMS[2010] patients with Gd+ lesions (16.4 pg/ml, IQR 9.3-31.3 pg/ml, n = 213) than in those without (10.2 pg/ml, IQR 7.2-
16.1 pg/ml, n = 218, p < 0.0005). F) ROC curves generated for either positive OCB or Gd+ lesion alone (AUC = 0.76, CI 0.70 - 0.83) or in addition to the 90th percentile of sNfL
(AUC = 0.84, CI 0.79 - 0.89). AUCs were compared using a Chi-square test (p = 0.035). G) Predictive analysis using SVM was performed yielding a prediction accuracy of 79% for OCBs
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higher proportion of patients without therapy (40%, 71/176) had higher
sNfL values after two years compared to baseline in contrast to only 31%
(120/392, p < 0.05) on “basic”, 24% (32/134, p < 0.05) on “moderate”
and 16% (17/107, p< 0.05) on “high” therapy (Fig. 3F). This also indicates
that longitudinal sNfL changes rather than absolute sNfL values at a given
time point might be indicative of disease activity and treatment stratifi-
cation. Most interestingly, we found a remarkable impact of diagnostic
classification on real-world treatment stratification. Compared to CIS
[2010] patients, fewer RRMS[2010] patients were on “basic” treatment
(RRMS[2010]: 53.7%, CIS[2010]: 72.4%), but received “moderate” (RRMS
[2010]: 25.4%, CIS[2010]: 15.8%) or highly active treatment (RRMS
[2010]: 20.9%, CIS[2010]: 11.8%) more frequently at year two (Fig. 3G).
Importantly, evaluation of CIS[2010] patients showed that all patients
but one on high therapy would have been classified as RRMS[2017]
according to the new criteria (Fig. 3H). These data demonstrate that
patients with initially high sNfL levels ended up on more efficient thera-
peutic agents two years later.
Where available, we analyzed current treatment decision at the
four-year follow-up and the number of therapy changes made up to
that point (no DMT: n = 137; “basic”: n = 209; “moderate”: n = 132;
“high”: n = 120, Fig. 4A). Intriguingly, without knowledge of sNfL lev-
els, high efficacy DMT (“high” or “moderate”) was initiated more
often in patients with higher sNfL levels both at baseline (13.2 pg/ml,
IQR 8.024.2 pg/ml, n = 304; 9.8 pg/ml, IQR 6.715.4 pg/ml, n = 301;
p < 0.0005, Fig. 4B) and two-year follow-up (8.2 pg/ml, IQR
6.011.8 pg/ml, n = 304; 7.6 pg/ml, IQR 5.911.0 pg/ml, n = 301;
p = 0.007). Being treated with at least one higher efficacy DMT was
associated with a stronger relative decrease in sNfL levels compared
to patients never treated with more than “basic” DMT (p < 0.0005).
Furthermore, current sNfL levels at baseline or two-year follow up
were significantly correlated to the number of therapy changes
implemented in the subsequent two years of the observation period
(sNfL at baseline r = 0.179, p < 0.0005, Fig. 4C upper panel; sNfL at
two-year follow-up r = 0.133, p = 0.001, Fig. 4C lower panel).
Moreover, sNfL levels at two-year follow-up are increased in
patients undergoing escalation therapy within the next two years
compared to patients who stayed on the same therapy (“escalation”:
9.1 pg/ml, IQR 6.4-13.7 pg/ml, n = 107; “no escalation”: 7.7 pg/ml, IQR
5.911.2 pg/ml, n = 358, p = 0.001, Fig. 4D). On closer analysis, the
sNfL levels changed significantly differently over time, depending on
whether DMT was initiated/escalated, de-escalated or maintained in
the same class between two and four years of follow-up (p = 0.029).
The decision for “no escalation” was retrospectively confirmed by
lower sNfL levels at two-year follow-up compared to patients with
subsequent DMT initiation/escalation (7.1 pg/ml, IQR 5.810.4 pg/ml,
n = 50; 9.1 pg/ml, IQR 6.413.7 pg/ml, n = 107, p = 0.026, Fig. 4D).
Since different treatment strategies, namely early induction or later
escalation to higher efficacy DMT, are part of the current debate we
next separated all patients ending up in DMT groups “moderate” or
“high” at four-year follow-up on whether they were already in these
DMT classes at two-year follow up (“induction”: n = 153) or not
(“escalation”, n = 82, Fig. 4E). Supporting the potential of neurofila-
ment as a treatment biomarker we found a significant interaction
between treatment strategy and time on sNfL levels (p = 0.002).
Although patients in the “induction” group initially started with
higher baseline sNfL levels (14.4 pg/ml, IQR 8.228.9 pg/ml; 10.9 pg/
ml, IQR 7.519.1 pg/ml, p = 0.035), it declined much more sharply in
the first two years and even crossed the line of the “escalation” group
(7.8 pg/ml, IQR 6.012.3 pg/ml; 9.3 pg/ml, IQR 6.314.3 pg/ml,
p = 0.025). Nonetheless, the escalated therapeutic regimen betweenand/or Gd+ for discriminating CIS and RRMS according to 2017 McDonald criteria. Accuracy
variables. Group differences were analyzed by MannWhitney-U test and in cases of imba
reported as median. IQR: interquartile range, CIS: clinically isolated syndrome, DIS: dissem
sNfL: serum neurofilament, RRMS: relapsing-remitting multiple sclerosis, SVM: support ve
curve. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.year two and four was reflected by a stronger sNfL level decrease
leading to similar four-year follow-up sNfL levels in both groups
(“induction”: 6.2 pg/ml, IQR 4.88.7 pg/ml; “escalation”: 5.7 pg/ml,
IQR 4.47.9 pg/ml, p = 0.885). These data underline that longitudinal
assessment of sNfL levels might be a suitable approach for a real-
world comparison of different treatment stratification algorithms.
4. Discussion
We here evaluated sNfL in a large cohort of early MS patients and
provide supporting evidence for a role of starting longitudinal sNfL
assessments directly at the time point of first diagnosis. Specifically, sNfL
measurements have implications for i) diagnostic accuracy, ii) prognosis,
and iii) treatment decisionmaking in the four years after diagnosis.
In their 2017 revision of the McDonald diagnostic criteria, an
international panel of experts reached a consensus that makes it eas-
ier to establish a diagnosis of MS earlier than was possible with previ-
ous criteria. All CIS[2010] patients but one under high efficacy
therapies (n = 22) at follow-up would have already been diagnosed
as “RRMS” according to the 2017 criteria, providing robust data for
the superior diagnostic value of the 2017 diagnostic criteria. Previ-
ously, it was reported that increased CSF NfL in patients with radio-
logically isolated syndrome is an independent risk factor of
developing CIS [29] and for further development of clinically definite
MS in CIS patients [30]. Our findings even show that sNfL might be
useful in differentiating CIS from RRMS and may thus be considered
as a parameter for future revisions of diagnostic criteria if sNfL
methology can be robustly improved to allow for clinical routine care
settings. In fact, highest sNfL levels (in our patient cohort: cutoff 90th
percentile) increased sensitivity, specificity, and accuracy over OCB
or symptomatic Gd+ lesions to discriminate between CIS and MS. Fur-
ther studies should specifically focus on an additional diagnostic
value in patients with first disease symptoms and high initial sNfL
levels and thus a high likelihood of axonal damage and an established
CNS autoimmune inflammation. This notion is further supported by
our data showing that the risk predicting EDSS/MSFC after two years
based on baseline T2 lesions and Gd+ lesions was markedly elevated
by additionally including sNfL values.
In addition to a potential added value in the initial diagnosis of
patients, sNFL might also serve as a marker of treatment response, as
sNFL levels have been described to decrease after initiation of any
DMT [8,10,20] and specifically after switch from injectable therapies
to fingolimod [20] or after initiation of interferon-beta-treatment
[31]. We here present findings from one of the so far largest and earli-
est cohorts of MS patients correlating treatment responses with sNfL
levels. Importantly, data was acquired in a prospective, centralised
and highly standardised manner. The number of patients without
DMT after two years is comparable with other databases (e.g.,
MSBase ~30% of patients; [32] Swiss National Multiple Sclerosis
Cohort ~50% of patients [10]). However, patients in our study were
recruited at first demyelinating event and therefore earlier than in
other studies. After a two-year follow-up, untreated patients had an
elevated risk of higher sNfL levels than patients on DMT. It should be
noted that mean sNfL levels were nevertheless reduced in all patient
groups, and to a lesser extent in untreated patients, after two and
four years compared to baseline. Previously, sNfL levels were found
to be elevated 2 months before and 1 month after MRI scans showing
Gd+ lesions [31]. Inclusion criteria for our cohort demanded a mini-
mum interval of 30 days after relapse, but the exact duration of ele-
vated sNfL due to clinical or MRI disease activity has not yet been
established. This underlines the importance of both longitudinalincreased to 84% by including the 90th percentile of sNfL in addition to the above two
lanced sample sizes additionally validated by Bayesian analysis (C+D). sNfL levels are
ination in space, DIT: dissemination in time, Gd: gadolinium, OCB: oligoclonal bands,
ctor machine algorithm, ROC: receiver operating characteristic, AUC: area under the
Fig. 3. Relationship between 2017 McDonald criteria, therapeutic decision and sNfL levels at two-year follow-up. A) Percentage of patients receiving DMT in CIS[2010], RRMS[2010],
CIS[2010]!CIS[2017] and CIS[2010]!RRMS[2017] at two-year follow-up. B) sNfL levels at baseline were significantly higher in patients receiving DMT in the following two years
(11.8 pg/ml, IQR 7.5-20.9 pg/ml, n = 727) than patients without specific MS medication until two-year follow-up (9.5 pg/ml, IQR 6.4-14.1 pg/ml, n = 87, p = 0.002). C) Patients were
grouped into four classes based on the type of DMT they were receiving at year two follow-up. Median sNfL levels at baseline and two-year follow-up in four patient groups defined
above (no DMT: n = 176, basic: n = 392, moderate: n = 134 and high: n = 134). Baseline sNfL levels were correlated with the patient’s treatment group at two-year follow-up
(r = 0.223, p < 0.0005). D) There was a statistically significant two-way interaction regarding the between- and within-subject factors (time*treatment groups) on sNfL concentra-
tion (p < 0.0005). At baseline the high treatment group showed elevated sNfL concentration compared to all other groups (p < 0.0005). We observed no significant difference
between the treatment groups at two-year follow-up (ns) but a statistically significant effect of time on sNfL concentration for all four groups (p < 0.0005). E) Delta sNfL (two-year
follow-up minus baseline) for patients without DMT and on basic, moderate and high DMT. Calculation was adjusted for baseline sNfL values. High treatment versus basic treatment
S. Bittner et al. / EBioMedicine 56 (2020) 102807 9
10 S. Bittner et al. / EBioMedicine 56 (2020) 102807measurements and interpretation of sNfL results together with corre-
sponding clinical information. Strikingly, patients who were on high
efficacy therapies after two years, reflecting a severe early disease
course, had the highest initial sNfL levels and strongest relative
decrease. Furthermore, treatment decisions and escalation/de-escala-
tion decisions within the first four years were reflected by changes in
sNfL values. Future studies should further evaluate whether sNfL lev-
els are suited for prospective treatment stratification. Furthermore,
to pave the way into clinical practice, age-, demographic-, and
comorbidity-associated normative values as well as optimal fre-
quency of sampling and thresholds leading to distinct clinical deci-
sions in patient management, need to be internationally agreed on
and confirmed applying the exact same protocol prior to inter-labo-
ratory comparisons and accreditation. It should, however, be men-
tioned that at present, there is in parallel still work to do with
regards to missing mechanistic understanding about the underlying
pathophysiologic processes best reflected by sNfL. How do inflamma-
tory versus “diffuse” neurodegenerative processes impact sNfL both
on a short- and long-term scale, and what would be the add-on value
to use different surrogate parameters all considered to reflect neuro-
degenerative processes in MS (e.g., brain atrophy, OCT, sNfL).
Taken together, we report here findings in a large German multi-
centre cohort with early CIS/RRMS. In a clinical setting, determining
sNfL levels at time point of diagnosis and thereafter longitudinally
might not only increase the sensitivity of diagnostic criteria, but
could also  at least according to our findings based on the NationMS
cohort and German treatment practice in expert centres  provide
the next step towards personalised and optimised MS therapy.
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